<DOC>
	<DOC>NCT01065779</DOC>
	<brief_summary>This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of FOSAMAX PLUS / FOSAMAX PLUS D through collecting the safety information according to the Re-examination Regulation for New Drugs. Note: FOSAMAX PLUS D is known as FOSAMAX PLUS in several markets. FOSAMAX PLUS (70 mg/2800 IU) and FOSAMAX PLUS D (70 mg/5600 IU).</brief_summary>
	<brief_title>FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Participants who are treated with FOSAMAX PLUS / FOSAMAX PLUS D within label for the first time Participants who have a contraindication to FOSAMAX PLUS / FOSAMAX PLUS D according to the current local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>